Skip to main content

Table 1 Patients’ characteristics

From: A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma

Patient ID

Age/Sex

Stage

Meta site

MSKCC

Histology

Grade

Prior treatment

1802

72/F

pT3aN2M1

Lung, LN

Poor

Clear cell

2 > 3

Sunitinib

1803

72/M

pT3bN0M1

Liver, lung, bone

Poor

Clear cell

3 > 2

IFN-α, radiation

1806

72/F

pT4N1M1

Lung, LN

Intermediate

Clear cell

3

no

1808

75/M

pT3aN2M1

Lung, LN, bone

Intermediate

Unclassified

3

no

1812

61/M

pT1bN1M1

LN

Intermediate

Clear cell

2 > 1> > 3

no

1814

55/M

pT3aN0M1

Lung

Intermediate

Clear cell

2

no

1817

64/F

pT3bN1M1

Lung, LN, bone

Intermediate

Clear cell

3 > 2

no

1823

57/M

pT1N0M1

Lung, pleura

Intermediate

Clear cell

2 > 3

no

  1. MSKCC, Memorial Sloan Kettering Cancer Center risk criteria; LN, lymph node.